L
Lewis J. Rubin
Researcher at University of California, San Diego
Publications - 373
Citations - 60316
Lewis J. Rubin is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Pulmonary hypertension & Bosentan. The author has an hindex of 101, co-authored 370 publications receiving 57044 citations. Previous affiliations of Lewis J. Rubin include University of Texas Health Science Center at San Antonio & Silver Spring Networks.
Papers
More filters
Journal ArticleDOI
Corrigendum to: ‘Guidelines for the diagnosis and treatment of pulmonary hypertension’ [European Heart Journal (2009) 30, 2493–2537]. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)
Nazzareno Galiè,Marius M. Hoeper,Marc Humbert,Adam Torbicki,Jean-Luc Vachiery,Joan Albert Barberà,Maurice Beghetti,Paul A. Corris,Sean Gaine,J. Simon R. Gibbs,Miguel Ángel Gómez-Sánchez,Guillaume Jondeau,Walter Klepetko,Christian Opitz,Andrew J. Peacock,Lewis J. Rubin,Michael J. Zellweger,Gérald Simonneau +17 more
TL;DR: The 2009 ESC Practice Clinical Guidelines for the diagnosis and treatment of pulmonary hypertension included the endothelin receptor antagonist sitaxentan in an algorithm of evidence-based treatment for pulmonary arterial hypertension as mentioned in this paper.
Journal ArticleDOI
Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil.
Robyn J. Barst,Nazzareno Galiè,Robert Naeije,Gérald Simonneau,Roger Jeffs,Carl Arneson,Lewis J. Rubin +6 more
TL;DR: Intravenous epoprostenol improves exercise capacity and haemodynamics in PAH, and increases survival in idiopathic PAH (IPAH), and the safety profile for long-term subcutaneous treprostinil was consistent with previous short-term trials with no unexpected adverse events.
Journal ArticleDOI
An overview of the 6th World Symposium on Pulmonary Hypertension
TL;DR: The 6th WSPH comprised 124 experts, divided into 13 task forces, that began their work in January 2017 and presented their consensus opinions to an audience of 1376 participant attendees between February 27 and March 1, 2018 in Nice, France.
Journal ArticleDOI
Effects of Long-term Infusion of Prostacyclin (Epoprostenol) on Echocardiographic Measures of Right Ventricular Structure and Function in Primary Pulmonary Hypertension
Alan L. Hinderliter,Park W. Willis,Robyn J. Barst,Stuart Rich,Lewis J. Rubin,David B. Badesch,Berton M. Groves,Michael D. McGoon,Victor F. Tapson,Robert C. Bourge,Bruce H. Brundage,Spencer K. Koerner,David Langleben,Cesar A. Keller,Srinivas Murali,Barry F. Uretsky,Gary G. Koch,Shu Li,Linda M. Clayton,Maria M. Jöbsis,Shelmer D. Blackburn,James W. Crow,Walker Long +22 more
TL;DR: The echocardiographic characteristics of participants in this trial; the relationships of echOCardiographic variables to hemodynamic parameters, exercise capacity, and quality of life; and the echoprostenol changes associated with prostacyclin therapy are described.
Journal ArticleDOI
Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension.
TL;DR: It is demonstrated that prostacyclin can increase cardiac output and reduce pulmonary arterial pressure and resistance in PPH and sustained reductions in total pulmonary resistance during the infusion period.